Value Analysis of Ceftazidime Combined with Terbutalin in Patients with Acute Exacerbation of COPD  

作　　者：LIBo 

机构地区：[1]Zheng 'an County People's Hospital, Zunyi Guizhou 563400, China

出　　处：《外文科技期刊数据库(文摘版)医药卫生》2022年第7期218-221,共4页

摘　　要：Objective: To analyze the value of ceftazidime combined with terbutalin in patients with acute aggravation of COPD, Methods: In 70 patients with acute aggravation of COPD admitted from January 2020 to January 2022,70 patients were included, The random number table method is divided into the study group, the control group, 35 Cases each were presented in each group, In both groups of patients, routine treatment and treatment were conducted after the acute exacerbation of the disease, Control patients were treated with terbutalin, The study group combined the ceftazidime intervention, After treatment, the treatment effect, serum factor level and lung function index were evaluated 1 week after treatment. Results: The total clinical response rate of the study group was higher than the control group, the serum factors such as PDGF-B and IGF-1 were lower than the control group, and the proportion of forced expiration volume and forced lung capacity were more significant (P 0.05). Conclusion: Ceftazidime combined with terbutaline in the patients with acute aggravation of COPD can effectively promote the improvement of serum factor level and pulmonary function.

关 键 词：CEFTAZIDIME terbutalin chronic obstructive pulmonary disease acute exacerbation serum factor 

分 类 号：R563[医药卫生—呼吸系统]